Biomarin Pharmaceutical (BMRN) Change in Receivables (2009 - 2026)

Biomarin Pharmaceutical has disclosed Change in Receivables across 18 years of filings, most recently posting $7.2 million for Q1 2026.

• Quarterly Change in Receivables fell 87.57% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $177.6 million (up 58.43% YoY) and the FY2025 annual result came in at $228.1 million, up 293.81% from the prior year.
• Change in Receivables slipped to $7.2 million in Q1 2026, from $120.7 million in the prior quarter.
• Over five years, Change in Receivables peaked at $138.8 million in Q1 2023 and troughed at -$72.5 million in Q4 2024.
• A 5-year average of $33.3 million and a median of $37.7 million in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables jumped 46462.3% — and 2024, when it tumbled 224.02%.
• Tracing BMRN's Change in Receivables over 5 years: stood at $28.3 million in 2022, then surged by 106.83% to $58.5 million in 2023, then slumped by 224.02% to -$72.5 million in 2024, then jumped by 266.34% to $120.7 million in 2025, then slumped by 94.07% to $7.2 million in 2026.
• Business Quant data shows BMRN's Change in Receivables at $7.2 million in Q1 2026, $120.7 million in Q4 2025, and -$48.7 million in Q3 2025.